Search - tctmd.com

Displaying 141 - 160 of 216

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

October 29, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

October 18, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Daily News

Decline Seen in Readmissions After PCI in the Medicare Population

July 21, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Daily News

Good Warfarin Management Prevents Complications in A-fib Patients, Swedish Study Contends

April 21, 2016

News Daily News

US Cardiologists Are Underusing Oral Anticoagulation for A-fib

March 21, 2016

News Daily News

Real-World Traumatic Intracranial Bleeding in Elderly, Warfarin-Treated Patients a Bigger Problem Than Seen in Trials

March 09, 2016

News Daily News

抗凝诊所在非华法林方案的时代的崭新作用

March 01, 2016

News Daily News

Nuevos Roles de las Clínicas Especializadas en Anticoagulación en una Era de Opciones Sin Warfarina

March 01, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

March 01, 2016

News Daily News

Final CMS Decision Memo for Watchman Dumps Controversial Warfarin Contraindication

February 08, 2016

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

July 13, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.